Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma

Molecular imaging allows a noninvasive assessment of biochemical and biological processes in living subjects. Treatment strategies for malignant lymphoma depend on histology and tumor stage. For the last two decades, molecular imaging has been the mainstay diagnostic test for the staging of malignan...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 18; no. 8; p. 1639
Main Authors Kalimuthu, Senthilkumar, Jeong, Ju Hye, Oh, Ji Min, Ahn, Byeong-Cheol
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 27.07.2017
MDPI
Subjects
Animals
Biochemistry
Crystallization
Disease Models, Animal
Drug development
Drug Discovery
Drug Monitoring
Humans
Kidney stones
Lymphoma
Lymphoma - diagnostic imaging
Lymphoma - drug therapy
Medical imaging
Molecular Imaging
Molecular structure
Precision Medicine
Review
PET-CT
molecular imaging
bioluminescence
drugs
lymphoma
Online AccessGet full text
ISSN1422-0067
1661-6596
1422-0067
DOI10.3390/ijms18081639

Cover

More Information
Summary:Molecular imaging allows a noninvasive assessment of biochemical and biological processes in living subjects. Treatment strategies for malignant lymphoma depend on histology and tumor stage. For the last two decades, molecular imaging has been the mainstay diagnostic test for the staging of malignant lymphoma and the assessment of response to treatment. This technology enhances our understanding of disease and drug activity during preclinical and clinical drug development. Here, we review molecular imaging applications in drug development, with an emphasis on oncology. Monitoring and assessing the efficacy of anti-cancer therapies in preclinical or clinical models are essential and the multimodal molecular imaging approach may represent a new stage for pharmacologic development in cancer. Monitoring the progress of lymphoma therapy with imaging modalities will help patients. Identifying and addressing key challenges is essential for successful integration of molecular imaging into the drug development process. In this review, we highlight the general usefulness of molecular imaging in drug development and radionuclide-based reporter genes. Further, we discuss the different molecular imaging modalities for lymphoma therapy and their preclinical and clinical applications.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18081639